Literature DB >> 30471241

Comparison of Topical 5-Fluorouracil and Interferon Alfa-2b as Primary Treatment Modalities for Ocular Surface Squamous Neoplasia.

Nandini Venkateswaran1, Carolina Mercado1, Anat Galor2, Carol L Karp3.   

Abstract

PURPOSE: To compare the efficacy of topical 5-fluorouracil 1% (5FU) and interferon alfa-2b 1 MIU/mL (IFN) eye drops as primary treatment modalities for ocular surface squamous neoplasia (OSSN).
DESIGN: Retrospective, comparative, interventional case series.
METHODS: Fifty-four patients who received 5FU and 48 patients who received IFN as primary therapy for OSSN were included. Primary outcome measures were the frequency of clinical resolution and time to OSSN recurrence by treatment modality. Secondary outcome was the frequency of side effects with each therapy.
RESULTS: The mean age of patients was 68 years. More Hispanics were treated with 5FU. In a univariable analysis, frequency of OSSN resolution was higher with 5FU (96.3%, n = 52) than with IFN (81.3%, n = 39), P = .01. In a multivariable analysis, treatment modality did not remain a significant predictor of resolution. In patients whose OSSN resolved, time to resolution was similar with both agents, (5FU mean 6.6 months, standard deviation (SD) 4.5 vs IFN mean 5.5 months, SD 2.9, P = .17). Of the 52 eyes whose OSSN resolved with 5FU, 11.5% of lesions (n = 6) recurred, whereas of the 39 eyes whose OSSN resolved with IFN, 5.1% of lesions (n = 2) recurred, P = .46. Kaplan-Meier survival curves of OSSN recurrence were similar between groups (log-rank = 0.16). One-year recurrence rates were 11.4% with 5FU and 4.5% with IFN. Eyelid edema (P = .04) and tearing (P = .02) were more significant with 5FU.
CONCLUSIONS: This is the first direct comparison study between 5FU and IFN eye drops as primary treatment modalities for OSSN. Both modalities resulted in a high frequency of tumor resolution and low recurrence rates and are effective treatment options for OSSN.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30471241      PMCID: PMC6382615          DOI: 10.1016/j.ajo.2018.11.007

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  18 in total

1.  Whole exome profiling and mutational analysis of Ocular Surface Squamous Neoplasia.

Authors:  Nallely Ramos-Betancourt; Matthew G Field; Jesus H Davila-Alquisiras; Carol L Karp; Luis F Hernández-Zimbrón; Roberto García-Vázquez; Kristian A Vazquez-Romo; Gaofeng Wang; Jans Fromow-Guerra; Everardo Hernandez-Quintela; Anat Galor
Journal:  Ocul Surf       Date:  2020-07-24       Impact factor: 5.033

2.  Update on the Management of Ocular Surface Squamous Neoplasia.

Authors:  Umangi Patel; Carol L Karp; Sander R Dubovy
Journal:  Curr Ophthalmol Rep       Date:  2021-02-20

3.  Topical Chemotherapy for Treating Ocular Surface Squamous Neoplasia with a Combination of Interferon α-2b and 5-Fluorouracil.

Authors:  Wen Geng; Jia-Song Wang; Bing-Jie Shi; Hua-Tao Xie; Ming-Chang Zhang
Journal:  Ophthalmol Ther       Date:  2022-06-15

4.  Usefulness of Topical Interferon Alpha-2b Eye Drop as an Adjunctive Therapy Following Surgical Resection in Ocular Surface Squamous Neoplasia.

Authors:  Rina Kanaya; Satoru Kase; Kan Ishijima; Susumu Ishida
Journal:  In Vivo       Date:  2019 Nov-Dec       Impact factor: 2.155

Review 5.  Ocular surface squamous neoplasia: management and outcomes.

Authors:  Roland Hӧllhumer; Susan Williams; Pamela Michelow
Journal:  Eye (Lond)       Date:  2021-02-09       Impact factor: 4.456

Review 6.  Xeroderma pigmentosum: an updated review.

Authors:  Alexander Kc Leung; Benjamin Barankin; Joseph M Lam; Kin Fon Leong; Kam Lun Hon
Journal:  Drugs Context       Date:  2022-04-25

7.  Utility of high-resolution anterior segment optical coherence tomography in the diagnosis and management of sub-clinical ocular surface squamous neoplasia.

Authors:  Ann Q Tran; Nandini Venkateswaran; Anat Galor; Carol L Karp
Journal:  Eye Vis (Lond)       Date:  2019-08-27

Review 8.  Update on pharmacotherapy for ocular surface squamous neoplasia.

Authors:  Ghada Al Bayyat; Dan Arreaza-Kaufman; Nandini Venkateswaran; Anat Galor; Carol L Karp
Journal:  Eye Vis (Lond)       Date:  2019-08-12

9.  Management Issues in Conjunctival Tumours: Ocular Surface Squamous Neoplasia.

Authors:  Victoria M L Cohen; Roderick F O'Day
Journal:  Ophthalmol Ther       Date:  2019-11-23

10.  Ocular surface squamous neoplasia in New Zealand: a ten-year review of incidence in the Waikato region.

Authors:  Ruhella R Hossain; James McKelvie
Journal:  Eye (Lond)       Date:  2021-07-14       Impact factor: 4.456

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.